First, its dosing is complex. Second, some patients are hypersensitive to the drug, therefore its use requires careful monitoring.
It has rare but potentially fatal adverse effects involving the skin. The most serious adverse effect is a hypersensitivity syndrome consisting of fever, skin rash, eosinophilia, hepatitis, worsened renal function, and, in some cases, allopurinol hypersensitivity syndrome.
Expect to see more short covering early next year as some traders prefer to postpone tax treatment into 2014. This will be followed by January options expiration, contracting the hedge float at which point the stock will trade on its own merits.
Daily Short Sale Volume
Short Interest (Shares Short)
Days To Cover (Short Interest Ratio)
Short Percent of Float
Short Interest - Prior
Short % Increase / Decrease
Sentiment: Strong Buy
Geez, you guys ruined my christmas present thought - lol. Looks like nasdaq runs its business worse than the aca. Who said pvt enterprise is better than gvt?
Max claimed to have spoken to Wes Rose.
"The Affymax management team is The Brenner Group and Affy's President is Wes Rose, who I have spoken with a few times"
Could you ask them whether or not they can make an effort to revise the wikipedia page. Remove references to a drug trial on a condition for which Omontys was not approved and add the most important fact that Omontys is a once a month med. Its current condition seems to be a soapbox for shorts.
And if President Rose could find out when the recall was first mentioned to insiders especially the legal department. Its seems too much of a coincidence that the Valentines Day Letter, which recommended continued use, was the TRUE reason for shorting the stock just a week BEFORE the recall. Their legal dept was caught by the SEC using inside info before. The recall decision involving a Japanese partner could not happen in a day.
Gee uncle Bill you'll never believe what I heard at work today.
No, what was it sweet innocent naive Sally?
You get the picture.